Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02350309 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Effect of 2 Dosage Strengths of Lemborexant (E2006) on a Multiple Sleep Latency Test in Participants With Insomnia Disorder
A Phase 1 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 1
- Development phase
- 69
- Enrollment target
NCT02350309 is a Phase 1 study that has completed, run by Eisai. The registered enrollment target is 69 participants.
The verdict
NCT02350309, a Phase 1 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 69 participants
- Enrollment target
Study Summary
This is a single-dose, randomized, placebo-controlled, 3-way crossover study of 2 dosage strengths of lemborexant (5 mg and 10 mg) in participants with insomnia disorder.
Interventions
- DRUG Lemborexant 10 mg
- DRUG Lemborexant 5 mg
- DRUG Lemborexant-matched placebo.
- DRUG Flurazepam 30 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2014-12-13 |
| Est. Completion | 2015-04-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02350309
The ClinicalTrials.gov registry entry for NCT02350309 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Lemborexant 10 mg is the first listed.
NCT02350309 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02350309 about?
NCT02350309 is a clinical study titled "Study to Evaluate the Effect of 2 Dosage Strengths of Lemborexant (E2006) on a Multiple Sleep Latency Test in Participants With Insomnia Disorder". This is a single-dose, randomized, placebo-controlled, 3-way crossover study of 2 dosage strengths of lemborexant (5 mg and 10 mg) in participants with insomnia disorder.
What is the current status of trial NCT02350309?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 69 participants. The study started on 2014-12-13. Estimated completion is 2015-04-21.
What interventions are being tested in trial NCT02350309?
The interventions under investigation include: Lemborexant 10 mg (DRUG), Lemborexant 5 mg (DRUG), Lemborexant-matched placebo. (DRUG), Flurazepam 30 mg (DRUG).
Who is sponsoring clinical trial NCT02350309?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.